Page last updated: 2024-12-06

4-amino-4'-hydroxylaminodiphenylsulfone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-amino-4'-hydroxylaminodiphenylsulfone: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65387
CHEMBL ID1247
CHEBI ID186006
MeSH IDM0069520

Synonyms (32)

Synonym
[4,(4-hydroxylaminophenyl-sulfonyl)]aniline
n-[4-(4-aminophenyl)sulfonylphenyl]hydroxylamine
ni 1-146-1
32695-27-5
4-amino-4'-hydroxamine-diphenylsulphone
CHEMBL1247
n-hydroxydapsone
nsc742234
nsc-742234
4-(4-hydroxylaminophenyl-sulfonyl)aniline
dapsone hydroxylamine
n-[4-(4-aminophenyl)sulonylphenyl]hydroxylamine
CHEBI:186006
hads
dds-noh
benzenamine, 4-((4-aminophenyl)sulfonyl)-n-hydroxy-
4-hydroxylamino-4'-aminophenyl sulfone
4-amino-4'-hydroxylaminodiphenylsulfone
nsc 742234
unii-gs5815z51w
gs5815z51w ,
FT-0624446
n-hydroxy-4,4'-sulfonyldi-aniline
4-(hydroxyamino)-4'-aminodiphenyl sulfone
n-hydroxy-4,4'-sulfonyldi(aniline)
DTXSID30186361
AKOS030255828
J-018840
4-(4-(hydroxyamino)phenylsulfonyl)aniline
SB36609
Q27279256
dapsone-hydroxylamine 100 microg/ml in acetonitrile

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Paradoxically, other aspects of the glutathione-dependent cycling of the hydroxylamine metabolite may contribute to the major adverse reaction of the drug, agranulocytosis."( Dapsone toxicity: some current perspectives.
Coleman, MD, 1995
)
0.29
" The adverse reactions associated with the administration of dapsone are believed to be caused by metabolism to its hydroxylamine."( N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.
Gill, HJ; Park, BK; Tingle, MD, 1995
)
0.29
" Metabolism was assessed by high-pressure liquid chromatography-mass spectrometry and methemoglobin formation has been used as a toxic endpoint."( Comparison of the metabolism and toxicity of dapsone in rat, mouse and man.
Maggs, JL; Mahmud, R; Park, BK; Pirmohamed, M; Tingle, MD, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" When dapsone is given in combination with rifabutin, dapsone dosage adjustment may be necessary in light of the increase in dapsone clearance."( The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).
Greenspan, DL; Hooton, TM; Jacobson, M; Slattery, JT; Trapnell, CB; Unadkat, JD; Winter, HR, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonic acid derivative
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1653399Antimycobacterial activity against DDS resistant Mycobacterium smegmatis ATCC 607 infected in mouse2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID55882Inhibition of Dihydropteroate synthase of Mycobacterium 607 and log (1/MIC) was reported1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Quantitative structure-activity analysis in dihydropteroate synthase inhibition by sulfones. Comparison with sulfanilamides.
AID1653398Antimycobacterial activity against DDS sensitive Mycobacterium smegmatis ATCC 607 infected in mouse2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID55865Inhibition of dihydropteroate synthase of Escherichia coli1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Quantitative structure-activity analysis in dihydropteroate synthase inhibition by sulfones. Comparison with sulfanilamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (13.16)18.7374
1990's20 (52.63)18.2507
2000's6 (15.79)29.6817
2010's5 (13.16)24.3611
2020's2 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.12 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.00%)5.53%
Reviews4 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (85.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]